Holen Sie sich die Stockscreener-App
369.14
3.82%
13.57
Schlusskurs vom Vortag:
$355.57
Offen:
$357.28
24-Stunden-Volumen:
230.44K
Relative Volume:
0.83
Marktkapitalisierung:
$9.87B
Einnahmen:
$2.59B
Nettoeinkommen (Verlust:
$168.80M
KGV:
60.77
EPS:
6.0748
Netto-Cashflow:
$357.20M
1W Leistung:
-3.11%
1M Leistung:
-4.99%
6M Leistung:
+31.84%
1J Leistung:
+25.46%
1-Tages-Spanne:
$357.28
$369.40
1-Wochen-Bereich:
$353.30
$383.95
52-Wochen-Spanne:
$236.73
$396.23
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
369.14 | 10.19B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Rad Laboratories Drops 5.2% Amid Sector-Wide Selling - AlphaStreet
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Why Bio Rad Laboratories (BIO) Is Back In The Spotlight - Yahoo Finance
Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Revenue Breakdown – HAN:BUWA - TradingView
Bio-Rad Laboratories, Inc. (BIO) stock price, news, quote and history - Yahoo Finance Australia
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bio-Rad Laboratories (HAM:BUWA) Net Intangibles Purchase An - GuruFocus
Q1 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
RBC Capital reiterates Bio-Rad Labs stock rating on transformation outlook - Investing.com Nigeria
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - GlobeNewswire Inc.
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - GlobeNewswire Inc.
Bio-Rad Laboratories Inc Stock Warning Signs - GuruFocus
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth - Yahoo Finance
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
BIO: Multi-year transformation leverages technology, M&A, and restructuring to drive growth and margin expansion - TradingView
BIO: Multi-year transformation leverages digital PCR leadership and targeted M&A for growth - TradingView
Bio-Rad at bernstein healthcare forum: shift toward profitable growth - Investing.com
Bio-Rad at bernstein healthcare forum: shift toward profitable growth By Investing.com - Investing.com Canada
Bio-Rad Laboratories, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript - GuruFocus
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - Yahoo Finance
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher By Investing.com - Investing.com India
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - Quiver Quantitative
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring - The Manila Times
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - TradingView
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Challenges in the Medical Devices Sector - DirectorsTalk Interviews
Bio-rad Laboratories Stock Price Forecast. Should You Buy BIO? - StockInvest.us
Accelerating Legacy .NET Modernization at Bio-Rad with AWS Transform and Kiro - Amazon Web Services (AWS)
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues - Yahoo Finance
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Chromatography Reagents Market 2026-2030 | Global key Player; - openPR.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):